Neurogranin levels in cerebrospinal fluid: A new addition to the Alzheimer disease diagnostic toolbox

JAMA Neurology

Volumn 72, Issue 11, 2015, Pages 1237-1238

  Zetterberg, Henrik ^a,b   Blennow, Kaj ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; CALMODULIN; FLUORODEOXYGLUCOSE F 18; NEUROGRANIN; PROTEIN KINASE C; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; TAU PROTEIN;

ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; BRAIN ATROPHY; BRAIN CORTEX; BRAIN NERVE CELL; CARBOXY TERMINAL SEQUENCE; DENDRITIC SPINE; EDITORIAL; HIPPOCAMPAL CA1 REGION; HUMAN; MASS SPECTROMETRY; MICROGLIA; MILD COGNITIVE IMPAIRMENT; NERVE FIBER DEGENERATION; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN SYNTHESIS; SYNAPSE; CEREBROSPINAL FLUID; DISEASE COURSE; FEMALE; MALE; METABOLISM;

ALZHEIMER DISEASE; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MILD COGNITIVE IMPAIRMENT; NEUROGRANIN; SYNAPSES;

EID: 84946718780     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2015.2075     Document Type: Editorial

References (19)

1. Jansen WJ, Ossenkoppele R, Knol DL, et al; Amyloid Biomarker Study Group. Prevalence of cerebral amyloid pathology in persons without dementia: ameta-analysis. JAMA. 2015;313(19):1924-1938.
2. Ahmed RM, Paterson RW, Warren JD, et al. Biomarkers in dementia: clinical utility and new directions. J Neurol Neurosurg Psychiatry. 2014;85(12):1426-1434.
3. Hardy J. The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. J Neurochem. 2009;110(4):1129-1134.
4. Terry RD, Masliah E, Salmon DP, et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30(4):572-580.
5. Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL. Natural oligomers of the Alzheimer amyloid-β protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci. 2007;27(11):2866-2875.
6. Dorostkar MM, Zou C, Blazquez-Llorca L, Herms J. Analyzing dendritic spine pathology in Alzheimer's disease: problems and opportunities. Acta Neuropathol. 2015;130(1):1-19.
7. Represa A, Deloulme JC, Sensenbrenner M, Ben-Ari Y, Baudier J. Neurogranin: immunocytochemical localization of a brain-specific protein kinase C substrate. J Neurosci. 1990;10(12):3782-3792.
8. Zhong L, Cherry T, Bies CE, Florence MA, Gerges NZ. Neurogranin enhances synaptic strength through its interaction with calmodulin. EMBO J. 2009;28(19):3027-3039.
9. Fedorov NB, Pasinelli P, Oestreicher AB, De Graan PN, Reymann KG. Antibodies to postsynaptic PKC substrate neurogranin prevent long-term potentiation in hippocampal CA1 neurons. Eur J Neurosci. 1995;7(4):819-822.
10. Davidsson P, Blennow K. Neurochemical dissection of synaptic pathology in Alzheimer's disease. Int Psychogeriatr. 1998;10(1):11-23.
11. Davidsson P, Puchades M, Blennow K. Identification of synaptic vesicle, pre-and postsynaptic proteins in human cerebrospinal fluid using liquid-phase isoelectric focusing. Electrophoresis. 1999;20(3):431-437.
12. Kester MI, Teunissen CE, Crimmins DL, et al. Neurogranin as a cerebrospinal fluid biomarker for synaptic loss in symptomatic Alzheimer disease [published online September 14, 2015]. JAMA Neurol. doi:10.1001/jamaneurol.2015.1867.
13. Thorsell A, Bjerke M, Gobom J, et al. Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease. Brain Res. 2010;1362:13-22.
14. Kvartsberg H, Duits FH, Ingelsson M, et al. Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease [published online December 19, 2014]. Alzheimers Dement. doi:10.1016/j.jalz.2014.10.009.
15. De Vos A, Jacobs D, Struyfs H, et al. C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease [published online June 16, 2015]. Alzheimers Dement. doi:10.1016/j.jalz.2015.05.012.
16. Portelius E, Brinkmalm G, Tran AJ, Zetterberg H, Westman-Brinkmalm A, Blennow K. Identification of novel APP/Aβ isoforms in human cerebrospinal fluid. Neurodegener Dis. 2009;6(3):87-94.
17. Meredith JE Jr, Sankaranarayanan S, Guss V, et al. Characterization of novel CSF Tau and ptau biomarkers for Alzheimer's disease. PLoS One. 2013;8(10):e76523.
18. Brinkmalm A, Brinkmalm G, Honer WG, et al. SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer's disease. Mol Neurodegener. 2014;9:53.
19. Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010;9(1):119-128.